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Glasgow, Glasgow, UKDespite the high costs of treatment of people with kidney
disease and associated comorbid conditions, the amount of
reliable information available to guide the care of such
patients is very limited. Some treatments have been
assessed in randomized trials, but most such trials have
been too small to detect treatment effects of a magnitude
that would be realistic to achieve with a single intervention.
Therefore, KDIGO convened an international,
multidisciplinary controversies conference titled
“Challenges in the Conduct of Clinical Trials in Nephrology”
to identify the key barriers to conducting trials in patients
with kidney disease. The conference began with plenary
talks focusing on the key areas of discussion that included
appropriate trial design (covering identiﬁcation and
evaluation of kidney and nonkidney disease outcomes) and
sensible trial execution (with particular emphasis on
streamlining both design and conduct). Break out group
discussions followed in which the key areas of agreement
and remaining controversy were identiﬁed. Here we
summarize the main ﬁndings from the conference and set
out a range of potential solutions. If followed, these
solutions could ensure future trials among people with
kidney disease are sufﬁciently robust to provide reliable
answers and are not constrained by inappropriate
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creativecommons.org/licenses/by/4.0/).C hronic kidney disease (CKD) affects w10% of adultsin high-income countries,1,2 and its treatment isburdensome and costly, accounting for substantial
proportions of health budgets.3,4 It is now recognized as
an important cause of death, particularly in low- and
middle-income countries where diabetes is becoming com-
mon and resources for treatment are limited.5,6 Other con-
ditions affecting the kidney, such as acute kidney injury7,8
and kidney stone disease,9 also contribute a substantial
burden of morbidity and mortality. Despite the high indi-
vidual patient and societal burden of kidney diseases,
the amount of reliable information available to guide kidney
patient care is very limited.10 Although some treatments
have been assessed in randomized trials, most of these
have been too small to detect treatment effects of a magni-
tude that can realistically be achieved with a single interven-
tion (e.g., reductions of 15%–20% in major outcomes such
as death or disability). Experience to date indicates that con-
ducting trials in patients with kidney disease on the sort of
scale that has led to major therapeutic advances in other
specialties (e.g., oncology, diabetes, and cardiology11) is
challenging.297
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In order to discuss the most signiﬁcant barriers to conducting
trials in patients with kidney disease and to propose potential
solutions, KDIGO (Kidney Disease: Improving Global Out-
comes) convened an international multidisciplinary Contro-
versies Conference in Paris, France, titled “Challenges in the
Conduct of Clinical Trials in Nephrology” in September 2016.
The meeting began with plenary talks that aimed to identify
the key themes for discussion related to trial design (including
the speciﬁc topics of how to measure kidney and nonkidney
outcomes) and trial execution before 4 breakout groups
considered the key issues in detail. After each of the breakout
sessions, ongoing deliberations were reported and discussed
in plenary sessions. This paper synthesizes the main areas of
discussion, agreement, and remaining controversies addressed
at the conference. The conference agenda and selected pre-
sentations from the meeting are available on the KDIGO
website (http://kdigo.org/conferences/clinical-trials/).
The discussion was based on the general principle that, in
order to conduct a successful randomized trial, there are 4
main requirements: randomization of a sufﬁcient number of
patients (to ensure sufﬁcient numbers of outcomes); assur-
ance of adherence to the allocated treatment; reliable ascer-
tainment of relevant study outcomes; and appropriate
statistical analysis.12 These requirements can be met through
a combination of sound trial design and efﬁcient conduct.
Much of the discussion at the conference centered on the
concept of “streamlined” trial design, which focuses on the
main determinants of trial quality and avoids unnecessary
elements of design or conduct that increase cost and
complexity.13
Trial design (analogous to experimental design) and trial
conduct were considered separately. However, it should be
noted that many aspects of a trial’s design inﬂuence its
conduct and can therefore be decisive in determining whether
a trial is successful. Because of their large scope, discussions
about trial design were organized into 3 breakout groups that
considered the design of trials in kidney disease, how to
measure different kidney-speciﬁc outcomes, and assessment
of other outcomes. The fourth breakout group focused on
optimizing trial conduct. Table 1 brings together key ﬁndings
from the breakout groups with regard to challenges in the
design and conduct of randomized trials in patients with
kidney disease. More complete details are provided in the
following.
Optimizing trial design
General trial design considerations. The discussions iden-
tiﬁed important trial design principles that are generic but
inconsistently applied in trials among patients with kidney
disease, as well as issues that are speciﬁc to such trials.
Formulating the trial question. A key ﬁrst step when
planning a trial is to formulate the trial question. This should
be both clinically relevant (i.e., addressing a major area of
clinical uncertainty) and relevant to patients (i.e., aiming to
avoid an outcome or condition that patients themselves298consider signiﬁcant). Patients should be involved in discus-
sions when planning trials.
An important underlying principle in trials testing supe-
riority of an intervention is that the aim should always be to
compare treatment arms that differ substantially in their
expected effects on the primary outcome and to preserve this
separation for the duration of the trial. The likely magnitude
of this difference can sometimes be usefully tracked through
assessing differences in a surrogate variable between
randomized treatment groups (e.g., plasma low-density
lipoprotein cholesterol in the SHARP trial14), provided that
blinding at an individual participant level is strictly enforced.
Failure to maintain adequate adherence to study treatment
leads to a loss of separation between groups and loss of sta-
tistical power. This may be a particular problem in trials
among patients with CKD who are typically receiving mul-
tiple treatments, and are often required to attend clinics
frequently, and are particularly prone to drug toxicity and
intercurrent illnesses that may require the trial treatment to
be modiﬁed (as observed in the EVOLVE trial in which study
drug discontinuation was much higher than anticipated).15,16
Selecting a suitable trial population. As a general principle,
eligibility criteria should be practical and broad. This ensures
a widely generalizable result and facilitates efﬁcient recruit-
ment. Inclusion criteria should identify a suitable population
of patients who are likely to have the type of outcome that the
treatment is anticipated to prevent. Guideline committees
may help to maximize the size of eligible populations by
highlighting areas of uncertainty, by avoiding making rec-
ommendations where evidence is weak, and by stating where
placebo-controlled trials are needed.
Exclusion criteria should be constructed that exclude
patients who have a deﬁnite indication or contraindication for
at least 1 of the study treatments, who are likely to be non-
adherent to the trial protocol, or who are not expected to
survive for the duration of the trial. Therefore, patients who
would have obvious safety issues (from relevant comorbidity)
or who are at high risk of a potential pharmacologic inter-
action related to the intervention should generally be
excluded (although this might not always be necessary if a
Data and Safety Monitoring Board is charged with moni-
toring safety in speciﬁc patient groups). An important group
to exclude is those who are likely to stop allocated treatment
because of intolerance or nonadherence (“drop-out”) or who
are likely to start the study drug (or a drug with a similar
mode of action) outside of the trial (“drop-in”). It may be
possible to identify patients who are likely to be nonadherent
during a prerandomization “run-in” period so that they can
be withdrawn before being randomized. This helps to pre-
serve study power.17 Run-in periods may be particularly
beneﬁcial in trials of dialysis patients, a complex group for
which maintaining adherence to generally well-tolerated
medications can be difﬁcult.14,15
Calculating an appropriate sample size. Kidney disease has
a wide variety of causes, and many different pathophysiologic
mechanisms are responsible for disease initiation andKidney International (2017) 92, 297–305
Table 1 | Objectives in designing and conducting randomized trials and issues in the context of kidney disease
Trial objectives
Elements that help to achieve trial objectives
Difﬁculties in kidney diseaseStudy design Study procedures
Answer an important
question reliably
Differences between treatment(s) must
be important to patients
Sample size: needs to be determined by
realistic assumptions (treatment
effects, rates of adherence [drop-out/
drop-in], and contemporary event
rates), and is generally best
determined by a ﬁxed number of
primary outcomes (i.e., event driven)
Study duration: sufﬁcient time is required
for study treatments to exert beneﬁt
(or for any known hazards to emerge)
Outcome selection:
 Relevant to patients and must be
measurable without undue burden on
them
 Sensitive to the main beneﬁts and
hazards of the trial treatment(s)
Many treatments are already in use
despite a lack of reliable evidence of
safety or efﬁcacy. Nephrologists may
be reluctant to compare such
treatments with placebo.
Because of the difﬁculties of identifying
large numbers of eligible patients
(especially in rare diseases), trialists
may:
 assume unrealistically large relative
risk reductions (sometimes based on
implausible results of systematic re-
views or nonrandomized studies)
 fail to allow for often substantial
nonadherence, which severely di-
minishes statistical power
Many kidney disease trials have not
measured suitable outcomes. Common
problems include:
 Lack of relevance to patients, pre-
scribers, and payers
 Lack of consistency with outcomes in
other pivotal trials
 Use of total mortality, either alone or
as a component of a composite pri-
mary outcome, resulting in a lack of
statistical power
Effective recruitment Population selection:
 Trials should be relevant to a wide
range of patients who might in the
future be treated with the study
intervention
 Avoid unnecessary exclusions
Availability of large numbers of
potentially eligible patients from routine
databases, with prescreening (if feasible)
Pilot study experience
Trials of patients with kidney disease
often exclude large proportions of
patients, resulting in both difﬁculty with
recruitment and a lack of generalizability
Achieving good
adherence
Exclude participants likely to drop out or
drop in at screening or before
randomization
Use of a run-in
Procedures that are not onerous for trial
participants
Allow ﬂexibility in determining nontrial
treatments
Patients with kidney disease have a high
burden of medication and intervention
Nephrologists can become certain about




Outcome deﬁnition does not require
complex procedures or difﬁculties for
patients
Simple case report forms recording
outcomes
Multimodal sources of patient data
(patients, family members, primary care
physicians)
Maintaining contact with patients who
no longer wish to take study treatment
or attend clinics (e.g., by telephone
follow-up)
Use of registry data and electronic health
care records
Unbiased analysis Statistical analysis plan, including:
 Intention-to-treat analyses as primary
 Limited number of subgroup analyses
and only when hypotheses can be
stated in advance
 Clear demarcation of primary, sec-
ondary, and exploratory analyses
Underpowered trials and low adherence
resulting in “negative” results for the
primary outcome have previously led to
inappropriate emphasis on
underpowered subgroup analyses and
potentially biased on-treatment analyses
C Baigent et al.: Clinical trials in nephrology: a KDIGO conference report KD IGO execu t i ve conc lu s i onsprogression, as well as for its complications. This makes it
unlikely that a single treatment would have a large relative
effect on major outcomes (particularly on outcomes such as
death or progression to end-stage kidney disease). In deter-
mining sample size, therefore, particularly for large Phase 3Kidney International (2017) 92, 297–305outcome trials, it is important to avoid overly optimistic as-
sumptions about treatment effect size, even when there are
apparently large effects on disease biomarkers. In practice,
this means that relative risk reductions in major outcomes of
more thanw20% are unlikely to be observed. Nonetheless, in299
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relative risk reductions may still correspond to large re-
ductions in absolute risk and therefore be clinically and
economically worthwhile.
It is inappropriate to estimate relative risk reductions (for
major outcomes) from systematic reviews composed solely of
small randomized trials; such trials can only achieve statisti-
cally signiﬁcant results (and hence publication) if—by the
play of chance—their effect estimates are larger than the
truth, which means that such reviews will tend to yield
inﬂated effect size estimates.18 When the evidence from pre-
vious small trials is limited in this way, a trial that is capable of
detecting a realistically moderate effect (e.g., a 15%–20%
reduction in a major outcome) is more rational than one that
aims to detect an effect estimated in a systematic review.
When designing kidney trials, there may be considerable
uncertainty when estimating event rates owing to a lack of
contemporary data from population-based studies.19 In
addition, event rates derived from population-based registries
may not reﬂect those of an enrolled trial population. The
potential for high levels of nonadherence to study treatment,
which can have a particularly detrimental effect on study
power, should also be considered. Adequate drug exposure
and study power may therefore be achieved by planning on a
predeﬁned total number of primary outcomes and a mini-
mum duration of follow-up in a study population of
approximately the correct size. A Data and Safety Monitoring
Board can advise on early termination of a trial if convincing
evidence of harm or efﬁcacy emerges before trial completion
or if there are other reasons (e.g., irremediable failure to re-
cruit or futility) that make it inappropriate to continue.
Statistical analysis. The principles of statistical analysis for
randomized trials are well documented and should be applied
in trials among patients with kidney disease.12 For example,
intention-to-treat analyses should be speciﬁed for the primary
analysis. Several particular problems are commonly encoun-
tered. First, where sample sizes are limited, there has been a
temptation to overinterpret subgroup ﬁndings or where
nonadherence is a problem, to conduct potentially biased on-
treatment analyses. In superiority trials, such analyses should
be considered exploratory rather than conﬁrmatory, except
where the analysis plan provides a clear justiﬁcation for them
before database lock and consideration has been given to the
number of comparisons being made.
In reporting the results of a clinical trial, the primary
outcome should be emphasized, even if the results do not
support the intervention. However, the full interpretation of a
trial’s results should relate to the totality of evidence, meaning
the primary outcome plus secondary and safety outcomes.20
If evidence is indeed inconclusive, this is an acceptable and
valuable conclusion, and further randomized trials may still
be useful if uncertainty remains.
Selection of outcomes for assessing treatment effects
Measurement of kidney-speciﬁc outcomes. The choice of
outcome measures in trials designed to assess kidney disease300status (i.e., function, damage, or disease activity) should
depend on the disease setting and phase of clinical develop-
ment. Consideration should be given both to the stage of the
disease and how rapidly it is progressing. Table 2 provides a
matrix of general approaches to and strategies for selecting
endpoints. The measurement of activity of disease and kidney
structure, if available, may add useful information to mea-
sures of kidney function. Disease-speciﬁc markers (or out-
comes) that reﬂect the underlying pathophysiology or
molecular pathways of disease may be helpful in the setting of
primary kidney diseases such as systemic lupus erythemato-
sus, IgA nephropathy, and polycystic kidney disease. However,
in settings where progression of kidney disease is a multi-
factorial process, such as with hypertension or diabetes mel-
litus, a kidney-speciﬁc outcome may be best assessed using
the estimated glomerular ﬁltration rate (eGFR).21
When outcome measures reﬂect the underlying patho-
physiology of a disease, the effects of an intervention may be
large enough to detect reliably in small to medium sized
trials. Therefore, surrogate outcomes are suited to smaller
Phase 2 clinical trials used to establish proof-of-concept,
optimal drug dose, and information on tolerability. Markers
of glomerular or tubular damage, inﬂammation, ﬁbrosis, etc.,
or a combination of markers may be considered at this phase.
A demonstrable difference in the average eGFR (or change in
the eGFR) between treatment groups may also be possible in
small- to medium-size trials.
In larger Phase 3 trials, it may also occasionally be
appropriate for outcome measures in support of the primary
outcome to include measures of structural damage or disease-
speciﬁc markers. Acceptable surrogates include measuring
total kidney volume in autosomal dominant polycystic kidney
disease.22,23 However, such trials must be sufﬁciently large to
also provide reliable information on the safety of the inter-
vention. Changes in eGFR over time may remain a more
practical and acceptable method for assessing progression of
kidney disease in many trials (Table 2).24
Directly measured GFR may occasionally be necessary if a
treatment might inﬂuence variables used to measure eGFR
through mechanisms other than effects on glomerular ﬁltra-
tion (e.g., muscle mass changes or tubular secretion of
creatinine). In the pediatric population, most clinical research
is conducted in the setting of rare diseases, which, by deﬁ-
nition, have small disease populations. Even so, studies in
pediatric populations are subject to the same principles for
evaluating progression of CKD as in adults. However, using
creatinine as a marker of GFR is problematic in children
younger than 2 years of age because creatinine levels rise
rapidly during infancy. The European Medicines Agency
provides guidance on extrapolating efﬁcacy and safety data
from adults to children to inform pediatric investigation
plans.25
An important current issue is whether change in albu-
minuria is acceptable as a surrogate marker of CKD pro-
gression.26 In the context of nephrotic syndrome, large
changes in albuminuria are an acceptable marker of kidneyKidney International (2017) 92, 297–305




Early stage: CKD G1-G3a
(eGFR $45 ml/min per 1.73 m2)
 Slope of mGFR or eGFR or
 Surrogate outcomeb or
 Combinations of outcomes
30%40% decline in eGFR using repeat measurements
to rule out transient acute effectsc
Late stage: CKD G3b-G5
(eGFR <45 ml/min per 1.73 m2)
End-stage kidney disease or
30%40% decline in eGFRc
End-stage kidney disease
or doubling of serum creatinine level (or 40%–57% decline in eGFR)c
CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; mGFR, measured glomerular ﬁltration rate.
aFor example, in patients with macroalbuminuria.
bSurrogates may include measures of activity of disease (e.g., in lupus nephritis) or kidney structure (e.g., in adult polycystic kidney disease).
cThe added value of eGFRs outside the routine study visit schedule has not yet been demonstrated and they may be unnecessary.
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setting of structural damage, but it may not be in the setting
of hemodynamic dysfunction or acute reversible disease.
Albuminuria may also be an appropriate surrogate if there is
evidence that the effects of treatment are durable. Possible
endpoints for evaluating treatments include prevention of
incident macroalbuminuria, remission from macro-
albuminuria to normoalbuminuria, and a predetermined
decrease, such as a set quantitative change. More data are
needed to better understand whether and how changes in
albuminuria correspond to disease progression and how
changes can be meaningfully applied to designing trial end-
points.27 The US National Kidney Foundation, the US Food
and Drug Administration, and the European Medicines
Agency will convene a meeting on March 15 to 16, 2018, to
discuss these issues.28
Measurement of comorbidity and mortality. Outcomes that
measure aspects of disease status other than kidney structure
or function may be disease-speciﬁc morbidity or mortality
and can include assessments of quality of life or everyday
functioning or economic impact. Outcomes should capture
the expected, plausible treatment effects (beneﬁts and harms),
be relevant to patients and health care providers, and be
appropriate for the phase of clinical development. Excess
burden to patients, their families, health care providers, and
research staff should be avoided. When available, measure-
ment instruments that have operating characteristics known
to be within acceptable limits should be used.
In determining outcome measures, patient and caregiver
perspectives should be sought and considered for all clinical
trials in nephrology. Standard deﬁnitions for key core out-
comes identiﬁed as being important to patients on dialysis
or with kidney transplants are being developed by the
Standardised Outcomes in Nephrology initiative.29,30 For
example, outcomes that the Standardised Outcomes in
Nephrology initiative has identiﬁed to be important to pa-
tients on hemodialysis include mortality, functioning of
vascular access, and cardiovascular disease, but also include
symptoms such as fatigue, pruritus, cognitive function, and
functional limitations. The US Food and Drug Adminis-
tration has provided speciﬁc guidance on how Patient Re-
ported Outcomes, which include assessments of quality of
life, can be developed and validated to assess theseKidney International (2017) 92, 297–305symptoms to support labeling claims.31 Examples for which
streamlined Patient Reported Outcomes may be particularly
important include trials of treatments for anemia (alongside
outcomes related to clinical safety and efﬁcacy).
Composite outcomes should combine components that
make sense for the speciﬁc intervention, patient population,
and disease state and should be of approximately compa-
rable clinical importance. All-cause mortality is rarely an
appropriate primary outcome in kidney trials because it is
neither sensitive to any real effects on particular causes of
death nor generalizable to different types of patients. It is
preferable to create composite outcomes comprising related
events that are all likely to be inﬂuenced favorably by
treatment (and assess the effects on safety outcomes sepa-
rately). If kidney and cardiovascular outcomes are to be
combined in a single composite primary outcome, it is
important to ensure that sufﬁcient information will be
available on both disease components to be able to guide
treatment decisions. Similarly, the use of co-primary end-
points (for which an effect has only to be demonstrated on
one of them) is not generally appropriate unless each is in
some way relevant to patients and analyses of all such
endpoints are adequately powered.
When available and appropriate for the particular clin-
ical context under study, standardized disease outcome
deﬁnitions that are feasible to apply at scale should be
considered. However, if needed, new deﬁnitions should be
considered in special situations such as heart failure in the
context of dialysis. When a composite outcome is used, it is
important to assess the effects of treatment on its compo-
nents and related outcomes. Analyses of events that recur
(e.g., vascular access procedures or hospitalization for heart
failure) may be important to patients and payers, and
appropriate statistical methodology to analyze recurrent
events is available.32 Where continuous measures are used,
clinically important differences should be deﬁned and
justiﬁed.
Instruments assessing health-related quality of life can
assess the economic impact of a treatment to inform payers.
Application of such instruments should follow the same
principles as those for other patient populations without
kidney disease, and appropriately streamlined methods for
gathering such data should be included in trial designs.301
Table 4 | Strategies to improve recruitment into kidney
disease trials
Education
C Demonstrate to the kidney health community the value of research
participation using visual media (i.e., social media, charity/patient
advocacy group websites, webinars) and peer group discussion
C Provide nephrologists with examples of the importance of
uncertainty
C Develop annual kidney clinical trials education for the community
(providers and patients)
 Improve knowledge of the principles of clinical trial design and
conduct
 Identify global and local barriers to conducting quality trials
 Share successes/tools
C Increase trial awareness through local advertising and patient
advocacy groups
C Develop systems for peer review of protocols for new trialists
Improve information on potential trials
C Within individual health care systems and clinic settings:
 Create a readily accessible repository of current and planned trials
 Create or use existing electronic health care records or registries to
identify eligible patients (particularly for rare diseases)
Improve trial infrastructure
C Widen the type of health care services participating in trials
Incentivize trial participation
C Acknowledge clinical research activities (e.g., using continuing
medical education credits, “awards”)
C Nationally audit trial participation as a marker of quality of care
C Payers to reward randomization
Make randomization easy
C Simplify consent procedures
C Integrate trial systems into the electronic systems used in routine
practice
Cross-collaborate with other specialties
C Develop trials with diabetologists, cardiologists, and other specialists
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Increasing the number of large, important, and relevant
clinical trials will require a culture shift within the nephrology
community. A multipronged approach is required to improve
study conduct and help all stakeholders to better understand
the ways in which high-quality clinical trials improve patient
care. One practical solution for streamlining the conduct of
trials is integrating research processes and procedures into
routine care (as has been done so successfully in oncology,
diabetes, and cardiology33), and success in this depends on
improved community awareness.
Inefﬁciencies in clinical trial conduct jeopardize the ability
to address important clinical questions and are a disservice to
trial participants. Table 3 lists potential strategies to improve
the efﬁciency and effectiveness of clinical trials in nephrology
and in other disciplines. Such strategies would be expected to
enhance the rights of participants (e.g., by ensuring that
consent procedures provide information in an accessible
form) as well as their safety and well-being (e.g., by mini-
mizing the requirements for study visits and invasive tests or
by more effective methods of pharmacovigilance). This work
builds on the Quality by Design approaches developed by the
Clinical Trials Transformation Initiative.34,35
Recruitment. Increasing participation in clinical trials is a
major goal and requires a range of strategies (Table 4). Pa-
tients and clinicians should be made aware of the value of
research participation and the importance of randomization.
This could be done through education via videos, webinars,
targeted advertising strategies, or peer group discussions.
Educational efforts, both formal and informal, need to be
dedicated, consistent, and constant. Patient advocacy groups
for rare diseases have been successful at engaging patients and
providers about the meaning and value of research and are a
potential resource for ideas and collaboration.
Processes for informing patients and health care team
members about speciﬁc clinical trials should be systemically
embedded in health care communities. At individual centers,
repositories of current and planned studies should be acces-
sible via various internet portals, and information about
studies should be displayed in the waiting areas and ofﬁces ofTable 3 | Strategies for minimizing issues that have a
meaningful impact on the rights, safety, and well-being of
trial participants or on the reliability of the trial conclusions
(which will inﬂuence the care of future patients)
1. Facilitating efﬁcient and rapid recruitment
2. Streamlining the process of high-quality data collection (by assessing a
limited number of critical data elements)
3. Maximizing adherence to study treatment and minimizing loss to
follow-up
4. Improving the efﬁciency and appropriateness of trial monitoring
(including using risk-based central statistical processes)
5. Rationalizing safety monitoring and pharmacovigilance activity (with
more focus on the review of randomized comparisons of aggregated
data by the unblinded Data and Safety Monitoring Boards)
6. Tailoring adjudication methods to focus on those events in which
adjudication may materially inﬂuence interpretation of the results
302medical facilities. For recruiting into speciﬁc trials, it may be
helpful to institute a process of “prescreening” whereby
research coordinators develop lists of potentially eligible pa-
tients and, where permissible, provide those patients with
information about the trial and “preconsent” them. This then
enables recruitment to proceed rapidly once the trial receives
full ethical and regulatory approval (and also helps to identify
sites that will not have sufﬁcient patients to contribute).
Electronic health records may provide an opportunity to
identify large numbers of potential participants who may be
eligible and should be invited. Widespread invitation ensures
that patients are empowered to decide whether they want to
participate in a trial rather than waiting for their doctor to
hand-select them.
Research champions within countries and regions
should be recognized and identiﬁable. Clinical research
organizations, academic research organizations, and net-
works of trialists should be encouraged to share informa-
tion about the enrollment performance of individual study
sites. This could speed completion of enrollment and
reduce wasting of resources on poor performing sites.
Excellence in research should also be recognized by national
audits and by payers, with rewards given both for
randomization and success in achieving quality data and
completeness of follow-up.Kidney International (2017) 92, 297–305
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a clinical trial affect the ability to recruit patients, follow their
progress, and complete the trial. Inefﬁciencies in data collec-
tion increase trial costs, labor, and burden of participation (for
both participants and the research team). To date, trials in
patients with kidney disease have tended to collect too many
data ﬁelds, most of which do not contribute to answering the
main clinical question and lead to unnecessary complexity and
difﬁculty in recruiting.34,35 Researchers should identify small
core datasets required for each study, minimize the frequency
of measurements, and simplify the collection of data. The
speciﬁc processes developed for an individual study will vary
depending on the study’s purpose, type of intervention,
available resources, and stage of development.
Well-established national dialysis and transplant registries
in many countries provide an opportunity to streamline data
collection in trials. Focused kidney-speciﬁc templates that use
consistent terminology, deﬁnitions, and sets of variables could
be of value if these templates were integrated into registries or
electronic health records.
Depending on the circumstances, expensive central labo-
ratory analyses may not be essential where an outcome is a
measure of difference in a biomarker between randomized
arms. Variation in calibration for a biomarker between lab-
oratories has little impact on the magnitude of differences
between randomized groups. For example, in the SHARP
trial, analyses of differences in routine plasma (or serum)
creatinine measured every 6 months at local hospital labo-
ratories allowed low-cost, but reliable, assessment of the ef-
fects of ezetimibe/simvastatin on the progression of CKD.14
When using local laboratories, however, it is important to
know their reporting units, reference ranges, and analytic
methods to ensure that summary analyses are meaningful.
There is increasing evidence that veriﬁcation of clinical
outcome data (usually referred to as outcome adjudication)
may have little effect on the relative risk reductions reported
by trials and that this process could also be streamlined in
certain situations.36
Maximizing adherence to treatment and follow-up
procedures. Approaches such as using “run-in” periods to
identify patients who are unlikely to adhere to study treat-
ment and/or attend clinics,17 minimizing unnecessary data
collection, limiting excessive numbers of study visits (perhaps
by arranging follow-up by telephone or electronic health re-
cords where possible), and expediting in-person visits (e.g., by
avoiding lengthy waits in the hospital pharmacy) may all help
maintain adherence and follow-up (Table 1). Adherence
should be monitored centrally, and each study treatment
“dropout” should prompt investigation into the reason and
discussion as to whether study treatment can be restarted.
In clinical studies, the term withdrawal of consent is
problematic because of its lack of speciﬁcity and because it is
frequently confused with a participant’s wish to stop study
treatment or not undergo a certain trial procedure. Speciﬁc
levels of withdrawal from the protocol-speciﬁed follow-up,
which range from a patient not attending clinic visits butKidney International (2017) 92, 297–305perhaps agreeing to clinical note review to an absolute
withdrawal with no further data being provided, should be
embedded in case report forms. To better capture follow-up
data for patients who are no longer participating in a study,
patients could be asked to agree that electronic health records
can be accessed. This would allow for capturing information
about their outcomes, adverse events, and concomitant
medications during and after study participation.37 Engaging
general practitioners and primary care providers could also
help in establishing streamlined methods for complete study
participant follow-up.
Trial monitoring. Trial monitoring can be time-
consuming and resource intensive, and therefore simplifying
these processes can have a profound impact on reducing the
burden of the trial conduct. When using direct electronic data
entry, processes for trial monitoring and source data veriﬁ-
cation can become much more efﬁcient.38 For example, risk-
based approaches to monitoring (focusing on those data that
are critical to trial quality) and central statistical monitoring
(using study data to identify unusual patterns of perfor-
mance) can reduce and prioritize site visits.
Safety reporting should be tailored for each trial protocol.
In early phase development, rigorous detailed adverse event
ascertainment is necessary, but this level of event recording
may not be necessary when the safety proﬁle of a treatment is
well-known. During protocol development, regulators such as
the US Food and Drug Administration and European Medi-
cines Agency can advise on which speciﬁc adverse events need
to be collected and which do not. Regulators can also advise
on the level of information that needs to be collected. Clinical
narratives are burdensome, may reduce trial participation,
and should be focused only on those serious adverse events
where such data may be informative, such as suspected un-
expected serious adverse reactions.39 Reliable review of safety
during a trial is best achieved by examining randomized
comparisons of aggregated data by the unblinded Data and
Safety Monitoring Boards.
Conclusions
The lack of adequately powered randomized trials in
nephrology has led to a problematic imbalance between the
clinical need of patients with kidney disease and the amount
of reliable evidence to inform practice. This KDIGO confer-
ence highlighted some of the key challenges faced by those
trying to perform large trials. These include a lack of uncer-
tainty among nephrologists who have often adopted treat-
ments before adequate evidence of efﬁcacy or safety is
available, smaller treatment effects than were predicted from
effects on surrogate biomarkers, inappropriate selection of
outcomes including those with little relevance to patients or
unlikely to be affected by treatment (e.g., all-cause mortality),
difﬁculty in identifying large numbers of eligible patients,
high levels of nonadherence to study treatment by over-
burdened patients, and overcomplicated trial conduct
(Table 1). Adoption of the approaches outlined in this report
has the potential to dramatically improve the quality of303
KDIGO execu t i ve conc lu s i ons C Baigent et al.: Clinical trials in nephrology: a KDIGO conference reportclinical trials in nephrology and substantially enhance the
evidence base for the safe and effective treatment of patients
with kidney disease.
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